Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cardium Therapeutics, Inc. (CXM) Tackles Three Major Markets At Once

|Includes: Cardium Therapeutics, Inc (CXM)

Ask any physician or health care professional what America's biggest single health problem is and you will likely get an answer that points to cardiovascular disease and the lifestyle issues that promote it, such as obesity. Heart disease has long been the number one killer in the U.S., and various lifestyle factors have increasingly been implicated as a principal cause. Specifically, poor eating habits and a sedentary lifestyle have been shown to encourage obesity and type 2 diabetes. Type 2 diabetes, in turn, can lead to a number of serious problems, one of which is cardiovascular disease.

The link between lifestyle, diabetes, and cardiovascular disease is a major focus because of the numbers involved. The U.S. now has the highest rate of obesity in the world, with roughly 30% of all Americans listed as obese. The growth in obesity has helped fuel an alarming growth rate in diabetes, with some states experiencing a doubling of the diabetes rate in just 5 years. Diabetes is now known to feed heart disease, and approximately 600,000 people die annually in the U.S. from heart disease. Such numbers have generated a vast and growing market for health products and drugs that can address this chain of disease which threatens to cripple entire generations and dramatically affect the nation's economy.

California-based Cardium Therapeutics, a health sciences and regenerative medicine company, is unique in that its products directly address all three of these major markets.

• Cardium's lifestyle subsidiary, To Go Brands, produces all-natural health supplements that are designed for easy and convenient use, helping people to get the nutrition they need while losing weight.
• Cardium's Excellagen is an FDA-approved easy-to-use gel that has been shown to speed and improve the healing process for wounds, including their primary target market of foot wounds caused by diabetes.
• Cardium's Generx is the first-of-its-kind drug that actually promotes the growth of blood vessels around the heart, enhancing blood flow for heart disease patients, unlike other heart drugs that simply address the pain.

For additional information, visit

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for "The Mission Report" at

Please see disclaimer on the MissionIR website